Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy

Archives of Neurology

Volumn 58, Issue 2, 2001, Pages 241-246

  Friess, E ^a   Kuempfel, T ^a   Winkelmann, J ^a   Schmid, D ^a   Uhr, M ^a   Rupprecht, R ^a   Holsboer, F ^a   Trenkwalder, C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SHY DRAGER SYNDROME;

EID: 0035109758     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.2.241     Document Type: Article

References (17)

1. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease
2. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine
3. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease
4. Psychotic and depressive symptoms in Parkinson's disease: A study of the growth hormone response to apomorphine
5. A comparison of the growth hormone responses to clonidine and apomorphine in the same patients with endogenous depression
6. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease
7. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease
8. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease
9. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology
10. Cardiovascular and renin responses to head-up tilt tests in parkinsonism
11. Parkinsonism; onset, progression and mortality
12. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease
13. Cholinergic receptor control mechanisms for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man
14. L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans
15. Somatostatin inhibits (d-Arg6, Pro9-NEt) salmon gonadotropin-releasing hormone- and dopamine D1-stimulated growth hormone release from perifused pituitary cells of Chinese grass carp, Ctenopharyngodon idellus
16. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand
17. A study of dopaminergic sensitivity in Parkinson's disease: Comparison in "de novo" and levodopa-treated patients